APRETUDE

This brand name is authorized in Estonia, France, Croatia, Ireland, Italy, Lithuania, United States

Active ingredients

The drug APRETUDE contains one active pharmaceutical ingredient (API):

1 Cabotegravir UNII HMH0132Z1Q - CABOTEGRAVIR

Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Read about Cabotegravir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
APRETUDE Prolonged-release suspension for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AJ04	Cabotegravir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AJ Integrase inhibitors
Discover more medicines within J05AJ04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3045888, 3045899, 3045901
Country: FR	Base de données publique des médicaments	Identifier(s): 62595850, 67664503
Country: IT	Agenzia del Farmaco	Identifier(s): 050882012, 050882024, 050882036
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097789, 1097790, 1097791
Country: US	FDA, National Drug Code	Identifier(s): 49702-238, 49702-264